Global Adalimumab Market - 2020-2027
|阿达木单抗的全球市场：2020-2027 Global Adalimumab Market - 2020-2027|
|出版日期: 2020年11月04日||内容资讯: 英文||
Adalimumab is approved under the brand name Humira for the treatment of the Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn's Disease (CD), and Plaque Psoriasis (Ps). Adalimumab is a recombinant human IgG 1 monoclonal antibody that targets tumor necrosis factor (TNF). It acts by binding to the tumor necrosis factor (TNF) and inhibiting the its interaction with the p55 and p75 cell surface TNF receptors. It lyses surface tumor necrosis factor expressing cells. It is effective in modulating the biological responses induced or regulated by TNF involving the changes in the levels of adhesion molecules responsible for leukocyte migration.
Adalimumab is developed by using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system. It is supplied as either a single-use, prefilled pen or as single-use, 1 mL filled glass syringe.
The global adalimumab market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Rising Prevalence of Autoimmune Disorders is Driving the Growth of the Market
The market is driven by the increasing demand for the adalimumab with the increasing prevalence of the autoimmune diseases. According to the National Stem Cell Foundation (NSCF), approximately 4% of the world's population is suffering from one of autoimmune diseases. Rheumatoid arthritis, ankylosing spondylitis, crohn's disease, psoriatic arthritis, plaque psoriasis, and others are the most common autoimmune diseases. According to National Psoriasis Foundation, approximately 2% to 3% of the global population i.e., 125 million people are suffering from Psoriasis worldwide. Approximately, 30% of patients with Psoriasis develop psoriatic arthritis, a chronic inflammatory arthritis that leads to joint deformations and disability. Ankylosing spondylitis affects around 0.1% and 1.4% of people worldwide. It is most frequent in men in comparison to the women. According to the Arthitis Foundation, around 80% of people develops the symptoms of ankylosing spondylitis in age-group at or before age of 30 years. Around, 5% of patients would develop ankylosing spondylitis in age-group of 45 or older.
Favorable Reimbursement Coverage for Adalimumab is Boosting the Market Growth
The better availability of the reimbursement coverage for adalimumab shall stimulate the market growth. Around, 99% of national commercial, Medicare Part D, and Medicaid patients covers the adalimumab. Chinese regulators had also included adalimumab to the country's National Reimbursement Drug List (NRDL). Chinese regulators provide e an average of 61% in price cuts of adalimumab with pharma companies.
Adverse Effects Associated with the use of Adalimumab is Hampering the Market Growth
The market is hindered by the adverse effects associated with the use of the adalimumab. Several adverse effects such as nausea, abdominal pain, hyperlipidemia, hematuria, hypercholesterolemia, back pain, rash, headache, hypertension, and others are observed among the patients. Redness, swelling or pain is observed at the site of injection of the adalimumab. It also increases the risk of developing the fungal, bacterial, and viral infection that can spread through the body. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergilosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been observed among the patients treated with adalimumab.
COVID-19 Impact Analysis
The global adalimumab market has received immense impetus from the COVID-19 pandemic, as several institutes, organizations, and companies are focussing on evaluating the potential of adalimumab for the treatment of the COVID-19. There is increasing research and development activities for adalimumab for the COVID-19. It has been observed that the Covid-19 patients who had adminstered the anti-TNF therapies for the treatment of inflammatory bowel disease and inflammatory arthritis were less likely to be hospitalised. The anti-TNF therapies is effective in neutralisizing the TNF, a major component of the cytokine response part of the damaging excess inflammatory phase of COVID-19. Therefore, institutes, and organizations are focussing on conducting the clinical trials for examining the efficacy and safety of adalimumab among the patients with COVID-19. For instance, in October 2020, Researchers at the University of Oxford in the United Kingdom had planned to initiate a new clinical trial to evaluate the effectiveness of the adalimumab for the treatment of the COVID-19 patients in the community care settings, primarily in care homes. The clincial trial i.e., AVID-CC would be led by the Oxford Clinical Trials Research Unit (OCTRU) and would enrol up to 750 patients from community care homes.
According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, the prevalence of the Rheumatoid Arthritis (RA) was found to be 395.5 per 100,000 in the United States in 2017. Women are two to three times as likely to be affected in comparision to the men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.
Rheumatoid Arthritis segment is expected to hold the largest share in the Adalimumab market
By disease type, the market is classified as the rheumatoid arthritis, psoriatic arthritis, crohn's disease, ulcerative colitis, and others. The rheumatoid arthritis segment is anticipated to hold the largest share in the adalimumab treatment market. Rheumatoid arthritis is the most common autoimmune arthritis that affects the joints, connective tissues, muscle, tendons, and fibrous tissues. It is characterized by the joint pain, stiffness, swelling and decreased movement of the joints. It causes pain and swelling in the wrist and small joints of the hand and feet. Rheumatoid Arthritis can hamper the patient's mobility and lead to the permanent joint damage. The prevalence of rheumatoid arthritis is increasing worldwide. According to the World Health Organization (WHO), the prevalence of the rheumatoid arthritis ranges between the 0.3% and 1% across the globe. It is most frequent among the women in comparison to the men.
By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period
The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies is segmented to have the highest market growth due to the high availability of the adalimumab in the hospital pharmacies. There is growing usage of the adalimumab for the treatment of the autoimmune and skin disorders in the hosptials. Adalimumab is effective in reducing the pain, and swelling associated with the several disorders.
North America region holds the largest market share global Adalimumab market
North America region is dominating the global adalimumab market accounted for the largest market share in 2019 owing to the high prevalence of the Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, Plaque Psoriasis, and Ulcerative Colitis. According to the National Psoriasis Foundation, around one million people are being affected by Psoriatic Arthritis in the United States. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Plaque Psoriasis is the most frequent form of psoriasis that affects around 6.7 million adults in the United States. As per the National Institute of Health, the prevalence of Crohn's Disease was 201 per 100,000 in the United States.
The United States accounts for the highest market share due to the availability of the favorable reimbursement coverage for adalimumab. There is presence of the several market players developing adalimumab. There is increasing research and development activities for examining the potential of adalimumab for the treatment of other indications apart from the Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis. The availability of the advanced healthcare facilities and infrastructure shall stimulate the market over the forecasted period.
Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period
Asia-Pacific region is estimated to be the fastest-growing region in the global adalimumab market owing to the increasing prevalence of the autoimmune diseases with the increasing adoption of unhealthy lifestyle, stress in daily life & immune system malfunction. The growing elder population shall have positive impact on the market. According to the United Nations Report, there were around 87 million of population of age-group 65 years or over in India. There is increasing investment for the improvement of the healthcare facilities & infrastructure. There is increasing awareness regarding the autoimmune diseases shall have a positive impact on the market.
There is increase in the approval of the biosimilars of adalimumab due to the presence of favorable regulatory policies for biosimilars. For instance, in September 2020, Innovent Biologics, Inc. had received the approval for Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug from the National Medical Products Administration (NMPA) of China for the treatment of Rheumatoid Arthritis (RA), ankylosing spondylitis and psoriasis in China. The increasing domestic income and purchasing power of people shall boost the demand for adalimumab over the forecasted period.
The adalimumab market studied is a fragmented market with the presence of large number of market players. AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals, Novartis AG, and Pfizer Inc are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,
The global adalimumab market report would provide an access to an approx. 61 market data table, 58 figures and 230 pages.
Target Audience 2022
LIST NOT EXHAUSTIVE